Literature DB >> 8473749

Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3.

V Vĕtvicka1, W Reed, M L Hoover, G D Ross.   

Abstract

B lymphocytes and transformed B lymphoblastoid cell lines express CR2 (CD21, C3d/EBV-receptor) that is specific for C3 fragments generated by cleavage of C3b or spontaneously hydrolyzed native C3 (C3i) by the serum enzyme factor I and its cofactor, factor H. It had been shown previously that the Raji B cell line could be cultivated in serum-free medium supplemented with only transferrin and either OKB7 anti-CR2 mAb, C3d, or C3d-derived peptides containing the CR2 binding site. Because these agents appeared to function through ligation of CR2, it was unclear how native C3 could also serve as a growth factor, because C3 does not bind to CR2. It appeared possible that Raji cells might be able to use endogenous factors H and I to generate a CR2 ligand from C3, because previous studies had shown that Raji cells synthesized factor H and probably also synthesized factor I. PCR analysis was used to demonstrate factor I mRNA in Raji cells. Secretion of Raji cell factor I protein was confirmed by a sensitive mAb ELISA. Several B cell lines were examined for C3-dependent growth. Raji cells required both C3 (or OKB7) and transferrin for growth, whereas Wil-2 cells grew with transferrin alone and C3 enhanced the growth-promoting activity of transferrin. Two other B cell lines (Daudi and U698M), the T cell line 8402, and the U937 monocytoid cell line could not be sustained with transferrin plus C3. The C3-dependent growth of Raji cells was inhibited almost completely by either OX-23 anti-factor H or 052.11.3 anti-factor I mAb that also blocked the activity of serum-derived factor H or I, respectively. By contrast, there was no inhibition of growth by either OX-24 anti-factor H or OX-21 anti-factor I mAb that did not block factors H and I activity. After the spontaneous hydrolysis of native C3 to C3i, it is hypothesized that Raji cells convert C3i to iC3i with endogenous factors H and I, and then this iC3i serves as a growth factor by binding to membrane CR2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473749

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  A C3(H20) recycling pathway is a component of the intracellular complement system.

Authors:  Michelle Elvington; M Kathryn Liszewski; Paula Bertram; Hrishikesh S Kulkarni; John P Atkinson
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

Review 2.  Production of complement components by cells of the immune system.

Authors:  R Lubbers; M F van Essen; C van Kooten; L A Trouw
Journal:  Clin Exp Immunol       Date:  2017-03-24       Impact factor: 4.330

3.  Rat complement factor I: molecular cloning, sequencing and expression in tissues and isolated cells.

Authors:  G Schlaf; E Rothermel; M Oppermann; H L Schieferdecker; K Jungermann; O Götze
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

4.  The molecular basis of hereditary complement factor I deficiency.

Authors:  T J Vyse; B J Morley; I Bartok; E L Theodoridis; K A Davies; A D Webster; M J Walport
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

5.  Complement factor I promotes progression of cutaneous squamous cell carcinoma.

Authors:  Pilvi Riihilä; Liisa Nissinen; Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Markku Kallajoki; Reidar Grénman; Seppo Meri; Sirkku Peltonen; Juha Peltonen; Veli-Matti Kähäri
Journal:  J Invest Dermatol       Date:  2014-09-03       Impact factor: 8.551

6.  Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts.

Authors:  M L Grattone; C L Villiers; M B Villiers; C Drouet; P N Marche
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

7.  Structural basis for complement factor I control and its disease-associated sequence polymorphisms.

Authors:  Pietro Roversi; Steven Johnson; Joseph J E Caesar; Florence McLean; Kirstin J Leath; Stefanos A Tsiftsoglou; B Paul Morgan; Claire L Harris; Robert B Sim; Susan M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

8.  Molecular characterization of homozygous hereditary factor I deficiency.

Authors:  G V Baracho; V Nudelman; L Isaac
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

9.  The structure of an alternate form of complement C3 that displays costimulatory growth factor activity for B lymphocytes.

Authors:  Y Cahen-Kramer; I L Mårtensson; F Melchers
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.